Clinical and Experimental Metastasis This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Guidance of healthcare development for metastatic cancer patients as an example for setting incentives
(Source: Clinical and Experimental Metastasis)
Source: Clinical and Experimental Metastasis - December 15, 2019 Category: Cancer & Oncology Source Type: research

Prognostic role of 14q32.31 miRNA cluster in various carcinomas: a systematic review and meta-analysis
AbstractDeregulated miR-379/miR-656 cluster expression is considered as important for carcinogenesis and can be used as a potential prognostic marker. Hence, the meta-analysis was conducted to test the utility of miR-379/miR-656 cluster as a prognostic marker in various cancers. A literature search was performed using Web of Science, PubMed and Cochrane Library to obtain relevant studies and were subjected to various subgroup and bioinformatics analyses. Selected twenty-three studies contained 13 cancer types comprising of 3294 patients from 7 nations. Univariate and multivariate data showed an association of high expressi...
Source: Clinical and Experimental Metastasis - December 6, 2019 Category: Cancer & Oncology Source Type: research

Upfront citorreduction and hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with stage III-C serous epithelial ovarian cancer
AbstractThe main objective of this retrospective multicenter study, conducted by the Spanish Peritoneal Surgical Oncology Group (GECOP) was to analyze the survival outcomes of patients with stage IIIC serous epithelial ovarian cancer, after cytoreduction and intraoperative administration of hyperthermic intraperitoneal chemotherapy (HIPEC) with paclitaxel. Patients with stage IIIC serous epithelial ovarian cancer were recruited between May 2005 and October 2015, and treated by radical surgery using peritonectomy procedures, and HIPEC with paclitaxel. This multi-institutional retrospective study was carried out using a data...
Source: Clinical and Experimental Metastasis - December 5, 2019 Category: Cancer & Oncology Source Type: research

A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence
AbstractThe papillary thyroid carcinoma (PTC) usually shows an excellent prognosis. But some patients suffer recurrence after treatment. Recent progress in RNA sequencing (RNA-Seq) allows us to explore whole-transcriptomic gene expression profiles to develop RNA-seq based predictive model for stratifying the risk of recurrence of PTC. RNA-seq and clinical data from The Cancer Genome Atlas thyroid carcinoma cohort were divided chronologically into a training cohort (before 2011, n  = 240) and a validation cohort (after 2011, n = 239). A risk score model was developed in training cohort using univariate Cox analysis ...
Source: Clinical and Experimental Metastasis - December 1, 2019 Category: Cancer & Oncology Source Type: research

Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
AbstractBrain metastases are common in patients with non-small-cell lung cancer (NSCLC). The efficacy of bevacizumab, an anti-vascular endothelial growth factor (VEGF) humanized antibody, has been demonstrated in patients with nonsquamous NSCLC. We established a transplantable NSCLC cell line (Nluc-H1915) that stably expresses NanoLuc ® reporter and confirmed the correlation between total Nluc activity in tumor and tumor volume in vivo. SCID mice inoculated with these cells through the internal carotid artery formed reproducible brain metastases, in which human VEGF was detected. Next, after metastases were established in...
Source: Clinical and Experimental Metastasis - November 24, 2019 Category: Cancer & Oncology Source Type: research

Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes
AbstractTo determine the location patterns of distant metastases at initial staging and outcomes of ovarian, uterine, and cervical cancer patients. Data were obtained from the SEER database from 2010 to 2015. Analyses were performed using Kaplan –Meier and multivariate Cox proportional hazard methods. Of 3035 patients (median age: 63, range: 17–95) with stage IV gynecologic cancer, ovarian, uterine, and cervical cancers were present in 42%, 40%, and 18% of the cohort. The proportion of lung, liver, bone and brain metastases were identif ied in 38%, 57%, 4%, and 1% of ovarian cancer patients, 62%, 22%, 13%, and 3% of ut...
Source: Clinical and Experimental Metastasis - November 21, 2019 Category: Cancer & Oncology Source Type: research

The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells
AbstractPlatelets are primarily known for their contribution to hemostasis and subsequent wound healing. In addition to these functions, platelets play a role in the process of metastasis. Since the first study that suggested a metastasis-promoting function for platelets was published in 1968, various mechanisms have been proposed to explain how platelets contribute to the metastatic process. These include roles in the intravascular arrest of tumor cells, in tumor cell transendothelial migration, in the degradation of basement membrane barriers, in migration and invasion at the metastatic site, and in the proliferation of ...
Source: Clinical and Experimental Metastasis - November 21, 2019 Category: Cancer & Oncology Source Type: research

Quality of life in patients with liver tumors treated with holmium-166 radioembolization
AbstractHolmium-166 radioembolization is a palliative treatment option for patients with unresectable hepatic malignancies. Its influence on quality of life has not been evaluated yet. Since quality of life is very important in the final stages of disease, the aim of this study was to evaluate the effect of holmium-166 radioembolization on quality of life. Patients with hepatic malignancies were treated with holmium-166 radioembolization in the HEPAR I and II studies. The European Organization for Research and Treatment of Cancer QLQ-C30 and LMC21 questionnaires were used to evaluate quality of life at baseline, 1  week, ...
Source: Clinical and Experimental Metastasis - November 14, 2019 Category: Cancer & Oncology Source Type: research

Disparities in the use of stereotactic radiosurgery for the treatment of lung cancer brain metastases: a SEER-Medicare study
This study investigates potential disparities in the use of SRS to treat Medicare patients. Surveillance, Epidemiology, and End-Results cancer registry data for patients diagnosed between the years 2010 and 2012 were examined to identify lung cancer patients diagnosed with BM at the same time as their primary cancer (SBM). Medicare claims for SRS were identified; the odds of having SRS claims and hazards of mortality associated with those odds were examined with respect to various clinical and demographic characteristics. Of 74,142 Medicare-enrolled patients diagnosed with lung cancer, 9192 were diagnosed with SBM and 3259...
Source: Clinical and Experimental Metastasis - November 7, 2019 Category: Cancer & Oncology Source Type: research

Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArc ™) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis
AbstractStereotactic radiosurgery (SRS) is an effective treatment option for multiple brain metastases (BMs). Modern mono-isocentric techniques allow the delivery of multiple stereotactic courses, in the event of intracranial failure. Nevertheless, limited data on effectiveness and toxicity have been reported in comparison to WBRT. Aim of this retrospective matched-pair analysis was to compare patients affected by limited BMs treated with multiple SRS courses using a mono-isocentric, non-coplanar technique (HyperArc ™, Varian Medical System) to upfront WBRT. One hundred and two patients accounting for 677 BMs were treate...
Source: Clinical and Experimental Metastasis - November 5, 2019 Category: Cancer & Oncology Source Type: research

Companion canines: an under-utilised model to aid in translating anti-metastatics to the clinic
(Source: Clinical and Experimental Metastasis)
Source: Clinical and Experimental Metastasis - November 4, 2019 Category: Cancer & Oncology Source Type: research

Editorial series: cancer care in low- and middle-income countries
(Source: Clinical and Experimental Metastasis)
Source: Clinical and Experimental Metastasis - October 30, 2019 Category: Cancer & Oncology Source Type: research

Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer
In this report, we investigate the role of PSAT1 in migration and invasion potential in a subset of TNBC cell types. We found that the expression of PSAT1 increases with TNBC clinical grade. We also demonstrate that suppression of PSAT1 or phosphoglycerate dehydrogenase (PHGDH) does not negatively impact cell proliferation in TNBC cells that are not dependent on de novo serine synthesis. However, we observed that suppression of PSAT1 specifically alters the F-actin cytoskeletal arrangement and morphology in these TNBC cell lines. In addition, suppression of PSAT1 inhibits motility and migration in these TNBC cell lines, wh...
Source: Clinical and Experimental Metastasis - October 18, 2019 Category: Cancer & Oncology Source Type: research

NHE5 regulates growth factor signaling, integrin trafficking, and degradation in glioma cells
AbstractNa+/H+ exchanger 5 (NHE5) is enriched in neurons and cycles between recycling endosomes and plasma membranes and transports protons to the endosomal lumen as well as to the extracellular space. Although NHE5 expression is undetectable in normal astrocytes, C6 glioma cells express NHE5 at an elevated level. Using C6 cells as a model, here we demonstrate that NHE5 has an important role in tumor growth and tumor cell proliferation and invasion. Glioma xenografts originating fromNHE5-knockdown cells exhibited significantly slower growth than those fromNHE1-knockdown cells and control cells. Histological characterizatio...
Source: Clinical and Experimental Metastasis - October 7, 2019 Category: Cancer & Oncology Source Type: research

Breast cancer cells expressing cancer-associated sialyl-Tn antigen have less capacity to develop osteolytic lesions in a mouse model of skeletal colonization
In conclusion, breast cancer cells expressing STn antigen had less capacity for skeletal colonization, possibly due to impaired adhesive capability. (Source: Clinical and Experimental Metastasis)
Source: Clinical and Experimental Metastasis - October 7, 2019 Category: Cancer & Oncology Source Type: research